NEO.US NeoGenomics Inc

Healthcare Health Care Providers & Services USA Stocks
15.41 USD
Close of Nov 16, 2026
7.07 20.15
Market cap
USD 1.99B
P/E
-
P/B
2.59x
ROE
-3.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NEO.US undervalued?

Graham number

The Graham number of NeoGenomics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NeoGenomics Inc fundamental analysis

No fundamental analysis for NeoGenomics Inc yet.

NeoGenomics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detectin…

Full company profile